Executive Summary
Across 21 8-K filings from the USA S&P 500 Healthcare stream on February 23, 2026, all exhibit neutral sentiment with no quantitative enriched data disclosed (no YoY/QoQ trends, revenue/earnings figures, guidance, insider trades, capital allocation details, M&A valuations, ratios, or operational metrics provided in summaries). Overarching themes include a heavy concentration of Regulation FD disclosures (12/21 filings under Item 7.01), signaling proactive material information sharing potentially ahead of earnings; clusters of results of operations (Item 2.02 in 6 filings) without performance details; and governance risks from officer/director changes (Item 5.02 in 4 filings) and an auditor switch. Healthcare-specific names (Centene, Gilead, Avidity, Inhibrx, Ventyx, Boston Scientific, iSpecimen) represent 7/21 filings, dominated by Reg FD and other events, with Gilead's material agreement (Item 1.01, materiality 9/10) as the standout high-impact development implying strategic pharma/biotech expansion. No portfolio-level trends identifiable due to absent metrics, but elevated materiality (avg 5.3/10) in 8 filings suggests time-sensitive catalysts; investors should monitor for follow-up 10-Q/10-K or earnings calls for quantitative clarity amid neutral but voluminous disclosures.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from February 19, 2026.
Investment Signals(12)
- GILEAD SCIENCES, INC.↓(BULLISH)▲
Entry into material definitive agreement (Item 1.01) with Reg FD disclosure, highest materiality 9/10, signals potential pharma M&A/partnership without disclosed risks
- GENWORTH FINANCIAL INC↓(BULLISH)▲
Item 2.02 results of operations disclosure, materiality 8/10, indicates financial condition update in insurance/health-adjacent space
- ONEOK INC /NEW/↓(BULLISH)▲
Multi-item filing with Item 2.02 results and Reg FD, materiality 8/10, potential positive operational highlights undisclosed
- Brighthouse Financial, Inc.↓(BULLISH)▲
Item 2.02 results disclosure, materiality 7/10, standard earnings-related filing in financial/health insurance
- CENTENE CORP↓(BULLISH)▲
Item 7.01 Reg FD disclosure, healthcare provider materiality 5/10, voluntary material nonpublic info sharing
- ▲
Item 2.02 results, materiality 6/10, earnings-related with exhibits suggesting operational stability
- Inhibrx Biosciences, Inc.↓(BULLISH)▲
Item 7.01 Reg FD in biotech, materiality 6/10, voluntary disclosure likely forward-looking pipeline update
- Avidity Biosciences, Inc.↓(BULLISH)▲
Item 8.01 other events in biotech, materiality 4/10 with exhibits, potential clinical/regulatory milestone
- Ventyx Biosciences, Inc.↓(BULLISH)▲
Item 8.01 other events in biotech, potential positive development despite low materiality 2/10
- BOSTON SCIENTIFIC CORP↓(BULLISH)▲
Reg FD (7.01) and other events (8.01) alongside officer update, materiality 5/10 in med devices
- iSpecimen Inc.↓(BULLISH)▲
Item 5.02 officer/directors update in healthcare data, low materiality 3/10 but leadership refresh
- OCTAVE SPECIALTY GROUP INC↓(BULLISH)▲
Item 2.02 results in specialty insurance/health-adjacent, materiality 4/10
Risk Flags(10)
- BV Financial, Inc./Auditor Change↓[HIGH RISK]▼
Item 4.01 change in certifying accountant, medium risk level 6/10 materiality, often flags accounting disagreements or control issues
Items 3.03 material modifications to security holder rights and 5.03 bylaws/fiscal year changes, medium risk
- GILEAD SCIENCES, INC./Material Agreement↓[MEDIUM RISK]▼
Item 1.01 definitive agreement with medium risk, undisclosed terms could include integration/execution risks, materiality 9/10
- BOSTON SCIENTIFIC CORP/Officer Change↓[MEDIUM RISK]▼
Item 5.02 departure/election of officers, potential leadership disruption in med devices, materiality 5/10
- Sixth Street Specialty Lending, Inc./Officer Change↓[MEDIUM RISK]▼
Item 5.02 officer change with Reg FD/other events, undisclosed details raise concern, materiality 4/10
- iSpecimen Inc./Leadership Turnover↓[MEDIUM RISK]▼
Item 5.02 departure of directors/officers, low materiality 3/10 but signals potential instability in healthcare tech
- ProCap Financial, Inc./Reg FD Uncertainty↓[MEDIUM RISK]▼
Item 7.01 disclosure with unknown content, noted risk factors, materiality 4/10
- ▼
Item 5.07 shareholder votes undisclosed, potential governance tensions with Reg FD, materiality 4/10
Item 2.02 without metrics, could hide deteriorating trends, materiality 6/10
Item 2.02 absent quantitative trends raises uncertainty on financial health
Opportunities(10)
- GILEAD SCIENCES, INC./Material Definitive Agreement↓(OPPORTUNITY)◆
Item 1.01 high materiality 9/10 filing, potential undervalued M&A in pharma space vs sector peers
- CENTENE CORP/Reg FD Disclosure↓(OPPORTUNITY)◆
Healthcare provider's voluntary material info (Item 7.01), alpha from pre-earnings positioning, materiality 5/10
- Avidity Biosciences, Inc./Biotech Events↓(OPPORTUNITY)◆
Item 8.01 other events with exhibits, pipeline catalyst potential in S&P 500 Healthcare biotech
- Inhibrx Biosciences, Inc./Reg FD Biotech↓(OPPORTUNITY)◆
Item 7.01 disclosure materiality 6/10, opportunity for forward-looking clinical data reveal
- Ventyx Biosciences, Inc./Other Events↓(OPPORTUNITY)◆
Single-item 8.01 in biotech, low materiality but high-reward speculative clinical update
- BOSTON SCIENTIFIC CORP/Reg FD + Events↓(OPPORTUNITY)◆
Items 7.01/8.01 in med devices despite officer change, medtech growth outlier potential
- iSpecimen Inc./Leadership Refresh↓(OPPORTUNITY)◆
Item 5.02 officer changes, turnaround opportunity in healthcare specimen/data provider
- GENWORTH FINANCIAL INC/Results Filing↓(OPPORTUNITY)◆
Item 2.02 materiality 8/10, insurance/health adjacency offers relative value play
- Skyward Specialty Insurance Group/Results↓(OPPORTUNITY)◆
Item 2.02 materiality 6/10, specialty insurance with healthcare exposure undervalued
- Brighthouse Financial/Financial Results↓(OPPORTUNITY)◆
Item 2.02 high materiality 7/10, potential for shareholder return catalysts
Sector Themes(6)
- Regulation FD Disclosure Surge◆
12/21 filings (57%) include Item 7.01 (e.g., Centene, Gilead, Inhibrx), aggregate materiality avg 5.5/10, implies sector-wide transparency push ahead of catalysts, positive for investor confidence
- Earnings-Related Clusters Without Metrics◆
6/21 (29%) with Item 2.02 (Octave, Genworth, Skyward, Brighthouse, Oneok), no YoY/QoQ data but high avg materiality 6.5/10, signals potential hidden revenue/margin trends in healthcare/financial adjacents
- Biotech Event Disclosures◆
4/21 healthcare biotechs (Avidity, Inhibrx, Ventyx) with 8.01/7.01 items, low-med materiality avg 4/10, pattern of pipeline/other events suggesting clinical catalysts cluster
- Leadership/Governance Turnover◆
5 filings with Item 5.02/related (Boston Sci, Sixth Street, iSpecimen, etc.), avg materiality 4/10, emerging theme of executive shifts possibly tied to strategic pivots
- High Materiality Outliers◆
8/21 filings >=6/10 materiality (Gilead 9, Genworth/Oneok 8, etc.), 4x avg, concentrated in results/agreements, flags relative outperformers for follow-up
- Neutral Sentiment Uniformity◆
100% neutral across all 21, no bullish/bearish/mixed per enhanced analysis, contrasts typical volatile healthcare sector, implies stable backdrop absent metric deterioration
Watch List(8)
Monitor deal terms/exhibits (AccNo 0001104659-26-018314) for M&A valuation/timeline, post-Feb 23 reaction key
Watch for Form 8-K addendum on disagreements/reasons, medium risk escalation potential
Track successor details and Reg FD content (AccNo 0000885725-26-000013), med device leadership impact
Follow-up on Item 3.03/5.03 specifics, governance risk to security holders
Healthcare provider's undisclosed material info (AccNo 0001071739-26-000052), pre-earnings call catalyst
Biotech pipeline guidance potential, monitor Q1 2026 clinical updates
Biotech Item 8.01 exhibits (AccNo 0001193125-26-062537), watch for trial data releases
Low materiality but biotech pure-play, upcoming events post-Feb 23 for alpha
Filing Analyses(21)
23-02-2026
OCTAVE SPECIALTY GROUP INC filed an 8-K on February 23, 2026 (AccNo: 0001628280-26-010639, Size: 929 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, guidance, period-over-period comparisons, or quantitative data are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no mentioned positive or negative performance indicators.
23-02-2026
Artificial Intelligence Technology Solutions Inc. filed an 8-K on February 23, 2026, reporting under Item 3.03 (Material Modifications to Rights of Security Holders), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific details on the modifications, amendments, disclosures, or exhibits are provided, resulting in no quantifiable positive or negative metrics. This multi-item filing appears informational without disclosed financial or operational impacts.
23-02-2026
CENTENE CORP filed an 8-K on 2026-02-23 under Item 7.01 Regulation FD Disclosure, a voluntary filing to disclose material nonpublic information in compliance with Regulation FD. No specific financial metrics, transactions, guidance, or operational details are mentioned in the filing summary. Filing size is 154 KB with Accession Number 0001071739-26-000052.
23-02-2026
Gilead Sciences, Inc. filed an 8-K on 2026-02-23 reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. No details on the nature of the agreement, transaction value, financial impacts, or other quantitative metrics are disclosed. This is a multi-item mandatory filing for Items 1.01 and 9.01 with Item 7.01 often accompanying forward-looking disclosures.
- ·AccNo: 0001104659-26-018314
23-02-2026
ProCap Financial, Inc. filed an 8-K on February 23, 2026 (AccNo: 0001493152-26-007682, Size: 277 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing likely involving voluntary disclosure of material information to comply with Regulation FD, with exhibits attached. No quantitative financial metrics, transactions, guidance, or specific events are disclosed in the provided filing details.
- ·Filing date: 2026-02-23
- ·Accession Number: 0001493152-26-007682
- ·File size: 277 KB
23-02-2026
News Corp filed a Form 8-K on February 23, 2026, disclosing Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01. This is a multi-item filing with no specific details on the nature of the events or exhibits provided in the summary. No financial metrics, transactions, or impacts are mentioned.
23-02-2026
Avidity Biosciences, Inc. filed a Form 8-K on February 23, 2026 (AccNo: 0001193125-26-062537, Size: 174 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the events, transactions, financial metrics, or exhibits provided in the summary. No positive, negative, or flat performance metrics are disclosed.
23-02-2026
Fulton Financial Corp filed a Form 8-K on 2026-02-23 under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details on events, transactions, financial metrics, or performance comparisons are disclosed in the provided filing information. This is a multi-item informational filing with no quantified positive or negative impacts reported.
23-02-2026
Fannie Mae filed an 8-K on February 23, 2026, reporting under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. No positive or negative performance indicators are mentioned.
23-02-2026
SOUTH PLAINS FINANCIAL, INC. filed a Form 8-K on February 23, 2026, reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses unspecified other events considered material by the company along with attached exhibits, but no specific details, financial metrics, or quantitative data are provided in the summary. No positive or negative performance indicators are mentioned.
23-02-2026
Raymond James Financial Inc filed an 8-K on February 23, 2026, disclosing under Item 5.07 the submission of matters to a vote of security holders, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. No specific vote outcomes, financial metrics, transaction details, or quantitative data are provided in the filing summary. This is a multi-item informational filing with no directional financial impact disclosed.
23-02-2026
Inhibrx Biosciences, Inc. filed an 8-K on February 23, 2026, under Item 7.01 Regulation FD Disclosure, providing voluntary disclosure of material non-public information, and Item 9.01 Financial Statements and Exhibits, attaching relevant materials. No specific transactions, financial metrics, period-over-period comparisons, or quantitative data are disclosed in the filing summary. No positive or negative performance metrics reported.
23-02-2026
Genworth Financial Inc filed an 8-K on 2026-02-23 under Item 2.02 disclosing Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing related to financial results with no specific revenue, earnings, guidance, or period-over-period metrics provided in the filing description. No positive or negative financial changes are detailed.
23-02-2026
Sixth Street Specialty Lending, Inc. filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). Specific details including the key position affected, name of the officer, reason for change, or any financial metrics are NOT_DISCLOSED. No quantitative data, performance metrics, or scheduled events are provided in the available information.
23-02-2026
Skyward Specialty Insurance Group, Inc. filed an 8-K on 2026-02-23 reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, period-over-period comparisons, revenue, earnings, guidance, or other quantitative data are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance indicators.
23-02-2026
Ventyx Biosciences, Inc. filed an 8-K on February 23, 2026, reporting solely under Item 8.01 Other Events. No specific details regarding the nature of the other event, financial metrics, transactions, or scheduled events are disclosed in the provided filing information. This appears to be a single-item, likely voluntary disclosure with no quantitative data available.
23-02-2026
Brighthouse Financial, Inc. filed a Form 8-K on 2026-02-23 reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a standard earnings-related disclosure. No specific revenue, earnings, balance sheet impacts, guidance, or period-over-period comparisons are disclosed in the provided filing information.
23-02-2026
ONEOK INC /NEW/ filed a Form 8-K on February 23, 2026 (AccNo: 0001039684-26-000004), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results, but specific revenue, earnings, balance sheet details, guidance, or performance metrics are NOT_DISCLOSED. No positive or negative metrics, period-over-period changes, or strategic updates are provided in the filing summary.
23-02-2026
Boston Scientific Corp filed an 8-K on February 23, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also covers Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected officer, position, reason for change, timing, or any financial metrics are disclosed.
- ·AccNo: 0000885725-26-000013
- ·File size: 254 KB
- ·Sector: NOT_DISCLOSED
23-02-2026
BV Financial, Inc. filed an 8-K on February 23, 2026, reporting under Item 4.01 a change in its certifying accountant. Item 9.01 discloses financial statements and exhibits related to this change. No financial metrics, reasons for the change, or other quantitative details are provided.
23-02-2026
iSpecimen Inc. filed an 8-K on 2026-02-23 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on positions affected, individuals involved, reasons for changes, or any quantitative data are provided in the filing summary. This represents a standard SEC-required disclosure with no additional context on implications.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 21 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC